Pentameric C-reactive protein is a better prognostic biomarker and remains elevated for longer than monomeric CRP in hospitalized patients with COVID-19.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Lausanne : Frontiers Research Foundation]
    • Subject Terms:
      COVID-19*; Humans ; C-Reactive Protein ; SARS-CoV-2 ; Pandemics ; Prognosis ; Biomarkers
    • Abstract:
      The differing roles of the pentameric (p) and monomeric (m) C-reactive protein (CRP) isoforms in viral diseases are not fully understood, which was apparent during the COVID-19 pandemic regarding the clinical course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Herein, we investigated the predictive value of the pCRP and mCRP isoforms for COVID-19 severity in hospitalized patients and evaluated how the levels of the protein isoforms changed over time during and after acute illness. This study utilized samples from a well-characterized cohort of Swedish patients with SARS-CoV-2 infection, the majority of whom had known risk factors for severe COVID-19 and required hospitalization. The levels of pCRP were significantly raised in patients with severe COVID-19 and in contrast to mCRP the levels were significantly associated with disease severity. Additionally, the pCRP levels remained elevated for at least six weeks post inclusion, which was longer compared to the two weeks for mCRP. Our data indicates a low level of inflammation lasting for at least six weeks following COVID-19, which might indicate that the disease has an adverse effect on the immune system even after the viral infection is resolved. It is also clear that the current standard method of testing pCRP levels upon hospitalization is a useful marker for predicting disease severity and mCRP testing would not add any clinical relevance for patients with COVID-19.
      Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision
      (Copyright © 2023 Hopkins, Nordgren, Fernandez-Botran, Enocsson, Govender, Svanberg, Svensson, Hagbom, Nilsdotter-Augustinsson, Nyström, Sjöwall, Sjöwall and Larsson.)
    • References:
      ISRN Inflamm. 2013 Sep 14;2013:379040. (PMID: 24167754)
      Front Immunol. 2021 Mar 16;12:644213. (PMID: 33796111)
      Circ Res. 2005 Sep 30;97(7):690-7. (PMID: 16123332)
      Health Sci Rep. 2022 Oct 07;5(6):e868. (PMID: 36248353)
      Int J Biochem Cell Biol. 2005 Feb;37(2):320-35. (PMID: 15474978)
      J Osteopath Med. 2021 Sep 30;121(12):869-873. (PMID: 34592071)
      Eur J Clin Invest. 2023 Jan;53(1):e13882. (PMID: 36190270)
      J Autoimmun. 2002 Nov;19(3):147-54. (PMID: 12419285)
      Circulation. 2014 Jul 1;130(1):35-50. (PMID: 24982116)
      Cureus. 2022 Aug 21;14(8):e28229. (PMID: 36017482)
      Front Med (Lausanne). 2021 Jul 22;8:714426. (PMID: 34368201)
      Int J Mol Sci. 2023 Jan 20;24(3):. (PMID: 36768404)
      SAGE Open Med. 2021 Oct 11;9:20503121211050755. (PMID: 34659766)
      Clin Infect Dis. 2020 Nov 19;71(16):2174-2179. (PMID: 32445579)
      Circulation. 2004 Oct 26;110(17):2713-20. (PMID: 15492312)
      J Exp Med. 2000 Nov 6;192(9):1353-64. (PMID: 11067883)
      Front Immunol. 2022 Aug 08;13:931039. (PMID: 36003367)
      Front Immunol. 2018 Apr 13;9:754. (PMID: 29706967)
      Immunity. 2020 Jul 14;53(1):19-25. (PMID: 32610079)
      Int J Epidemiol. 2021 May 17;50(2):420-429. (PMID: 33683344)
      Intensive Care Med. 2002 Mar;28(3):235-43. (PMID: 11904651)
      Front Immunol. 2023 Jan 18;13:1105343. (PMID: 36741367)
      Front Med (Lausanne). 2021 Dec 02;8:791716. (PMID: 34926532)
      Int J Infect Dis. 2020 Jul;96:467-474. (PMID: 32425643)
      J Med Biochem. 2020 Oct 02;39(4):500-507. (PMID: 33312067)
      Front Immunol. 2018 Jun 07;9:1302. (PMID: 29951057)
      Lab Invest. 2021 Dec;101(12):1550-1560. (PMID: 33767361)
      Front Immunol. 2018 Jun 12;9:1351. (PMID: 29946323)
      Arthritis Res Ther. 2022 Jun 11;24(1):139. (PMID: 35690780)
      Nat Med. 2020 Oct;26(10):1636-1643. (PMID: 32839624)
      Front Immunol. 2023 Jan 04;13:1082912. (PMID: 36685582)
      Am J Med Sci. 2000 Feb;319(2):79-83. (PMID: 10698090)
      Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi5-9. (PMID: 23221588)
      Front Immunol. 2022 Mar 04;13:866379. (PMID: 35309334)
    • Contributed Indexing:
      Keywords: COVID-19; CRP; SARS-CoV-2; isoforms; prognostic marker
    • Accession Number:
      9007-41-4 (C-Reactive Protein)
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20230919 Date Completed: 20230920 Latest Revision: 20230920
    • Publication Date:
      20230920
    • Accession Number:
      PMC10505432
    • Accession Number:
      10.3389/fimmu.2023.1259005
    • Accession Number:
      37724104